{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mambelli F"],"funding":["Fundação de Amparo à Pesquisa do Estado de Minas Gerais","Conselho Nacional de Desenvolvimento Científico e Tecnológico","Howard Hughes Medical Institute","Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","NIAID NIH HHS","Fundação de Amparo à Pesquisa do Estado de São Paulo","USP | Pro-Reitoria de Pesquisa, Universidade de São Paulo"],"pagination":["1925-1937"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10247535"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["210(12)"],"pubmed_abstract":["COVID-19 has accounted for more than 6 million deaths worldwide. Bacillus Calmette-Guérin (BCG), the existing tuberculosis vaccine, is known to induce heterologous effects over other infections due to trained immunity and has been proposed to be a potential strategy against SARS-CoV-2 infection. In this report, we constructed a recombinant BCG (rBCG) expressing domains of the SARS-CoV-2 nucleocapsid and spike proteins (termed rBCG-ChD6), recognized as major candidates for vaccine development. We investigated whether rBCG-ChD6 immunization followed by a boost with the recombinant nucleocapsid and spike chimera (rChimera), together with alum, provided protection against SARS-CoV-2 infection in K18-hACE2 mice. A single dose of rBCG-ChD6 boosted with rChimera associated with alum elicited the highest anti-Chimera total IgG and IgG2c Ab titers with neutralizing activity against SARS-CoV-2 Wuhan strain when compared with control groups. Importantly, following SARS-CoV-2 challenge, this vaccination regimen induced IFN-γ and IL-6 production in spleen cells and reduced viral load in the lungs. In addition, no viable virus was detected in mice immunized with rBCG-ChD6 boosted with rChimera, which was associated with decreased lung pathology when compared with BCG WT-rChimera/alum or rChimera/alum control groups. Overall, our study demonstrates the potential of a prime-boost immunization system based on an rBCG expressing a chimeric protein derived from SARS-CoV-2 to protect mice against viral challenge."],"journal":["Journal of immunology (Baltimore, Md. : 1950)"],"pubmed_title":["Recombinant Bacillus Calmette-Guerin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge."],"pmcid":["PMC10247535"],"funding_grant_id":["R01 AI116453","55007412","88887.504421/2020-00","465229/2014-0","303044/2020-9","88887.506612/2020-00","2023/02577-5","2017/24832-6","REDE-00140-16","401209/2020-2"],"pubmed_authors":["Dias GBM","Andrade JM","Homan EJ","Santos BPO","Abuna RPF","Heck N","Leite LCC","Mendes DAGB","de Araujo ACVSC","Mansur DS","Bafica A","Fabri VMR","Oliveira SC","da Silva JS","Mambelli F","de Magalhaes MTQ","Marinho FV"],"additional_accession":[]},"is_claimable":false,"name":"Recombinant Bacillus Calmette-Guerin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.","description":"COVID-19 has accounted for more than 6 million deaths worldwide. Bacillus Calmette-Guérin (BCG), the existing tuberculosis vaccine, is known to induce heterologous effects over other infections due to trained immunity and has been proposed to be a potential strategy against SARS-CoV-2 infection. In this report, we constructed a recombinant BCG (rBCG) expressing domains of the SARS-CoV-2 nucleocapsid and spike proteins (termed rBCG-ChD6), recognized as major candidates for vaccine development. We investigated whether rBCG-ChD6 immunization followed by a boost with the recombinant nucleocapsid and spike chimera (rChimera), together with alum, provided protection against SARS-CoV-2 infection in K18-hACE2 mice. A single dose of rBCG-ChD6 boosted with rChimera associated with alum elicited the highest anti-Chimera total IgG and IgG2c Ab titers with neutralizing activity against SARS-CoV-2 Wuhan strain when compared with control groups. Importantly, following SARS-CoV-2 challenge, this vaccination regimen induced IFN-γ and IL-6 production in spleen cells and reduced viral load in the lungs. In addition, no viable virus was detected in mice immunized with rBCG-ChD6 boosted with rChimera, which was associated with decreased lung pathology when compared with BCG WT-rChimera/alum or rChimera/alum control groups. Overall, our study demonstrates the potential of a prime-boost immunization system based on an rBCG expressing a chimeric protein derived from SARS-CoV-2 to protect mice against viral challenge.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-06-02T06:40:04.092Z","creation":"2026-05-25T03:07:32.102Z"},"accession":"S-EPMC10247535","cross_references":{"pubmed":["37098890"],"doi":["10.4049/jimmunol.2200731"]}}